In men with prostate cancer, 26.3% receiving leuprolide 3.75 mg did not reach testosterone ≤50 ng/dl.
In plain wordsIn men with prostate cancer, 26.3% receiving leuprolide 3.75 mg did not reach testosterone ≤50 ng/dl.
- Peptide
- Leuprolide
- Outcome
- Direction not reportedFailure to reach testosterone ≤50 ng/dl
- Study
n: not reported in source
- Outcome group
- Sex hormones and fertility · Endocrine and hormones
- Studied dose
- 3.75 mg monthly · 3 monthsAs given in this study (human).
Measurements
- Did not reach castration level (testosterone ≤50 ng/dl)
- 26.3%
- Leuprolide 3.75 mg
Source sentences
Of the patients that received leuprolide 3.75 mg, leuprolide 7.5 mg, and goserelin 3.6 mg, 26.3, 25, and 35%, respectively, did not reach castration levels, considering a testosterone cutoff ≤ 50 ng/dl.
4 context sentences(design, population, supporting numbers)
We evaluated prospectively 60 randomized patients with advanced prostate carcinoma, with indication for hormone blockade.
The patients were divided into 3 groups of 20: Group (1) received leuprolide 3.75 mg; Group (2) received leuprolide 7.5 mg; and Group (3) received goserelin 3.6 mg.
All groups were treated with monthly application of the respective drugs.
The patients' levels of serum testosterone were evaluated in two moments: before the treatment and 3 months after the treatment.